Compare GTLB & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTLB | ALKS |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.5B |
| IPO Year | 2021 | 2012 |
| Metric | GTLB | ALKS |
|---|---|---|
| Price | $26.31 | $30.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 14 |
| Target Price | ★ $49.35 | $43.43 |
| AVG Volume (30 Days) | ★ 5.4M | 1.6M |
| Earning Date | 03-04-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.55 | N/A |
| EPS | N/A | ★ 1.43 |
| Revenue | $759,249,000.00 | ★ $1,475,899,000.00 |
| Revenue This Year | $27.21 | $24.94 |
| Revenue Next Year | $18.86 | $3.47 |
| P/E Ratio | ★ N/A | $21.03 |
| Revenue Growth | ★ 30.93 | N/A |
| 52 Week Low | $23.45 | $25.17 |
| 52 Week High | $64.42 | $36.32 |
| Indicator | GTLB | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 36.13 | 38.26 |
| Support Level | N/A | $27.77 |
| Resistance Level | $50.47 | $31.69 |
| Average True Range (ATR) | 1.78 | 1.12 |
| MACD | -0.06 | -0.50 |
| Stochastic Oscillator | 30.22 | 19.26 |
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.